Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Advanced Medical Solutions reports solid end to 2024

(Sharecast News) - Tissue-healing technology specialist Advanced Medical Solutions Group reported robust growth for the year ended 31 December in an update on Tuesday, driven by strategic acquisitions and continued strength across its product portfolio. The AIM-traded company said it anticipated full-year revenue of £177m, up 40% from £126.2m in 2023.

EBITDA was expected to rise to between £40m to £40.5m, compared to £29.7m in the prior year, with adjusted pre-tax profit forecast at £29.2m to £29.7m, up from £25.9m.

The group said it completed two major acquisitions in 2024 - Syntacoll on 1 March and Peters Surgical on 1 July .

It said the integration of the businesses had progressed well, contributing significantly to its performance and enhancing its presence in the surgical product market.

Strong growth was seen across all surgical product categories, further solidifying the group's leadership in the sector.

In its wound care division, AMS said it had implemented strategic initiatives to adapt to shifting market dynamics.

The measures were expected to improve margins in 2025, positioning the business for continued profitability.

"The progress we made in the second half of 2024 has strengthened the confidence we have in the strategic rationale for the recent acquisitions of Peters Surgical and Syntacoll," said chief executive officer Chris Meredith.

"The synergistic benefits they represent to AMS, in terms of products, expertise, geographic reach and scale, are clearer than ever.

"As we start the new year as an enlarged and more competitive group, I remain confident and excited about the growth and opportunities that we expect in 2025 and beyond."

AMS said it would announce its full-year results on 19 March.

At 1322 GMT, shares in Advanced Medical Solutions Group were up 11.78% at 213.05p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Canaccord Genuity lowers target price on Castings
(Sharecast News) - Analysts at Canaccord Genuity lowered their target price on metal fabricator Castings from 340.0p to 325.0p on Thursday as it said things were "tough out there".
Jefferies hikes Plus500 target price after results, buyback
(Sharecast News) - Markets gave a negative reaction to Plus500's annual results and share buyback announcement, but that didn't stop Jefferies from hiking its target price by nearly a fifth and reiterated a 'buy' recommendation.
Thames Water receives High Court approval for emergency £3bn loan
(Sharecast News) - British water provider Thames Water has won the High Court backing for a £3bn emergency debt package just weeks before it was set to run out of cash.
Morgan Stanley upgrades Glencore, says concerns overdone
(Sharecast News) - Morgan Stanley upgraded Glencore on Tuesday to 'overweight' from 'equalweight' as it argued that concerns about deteriorating coal prices and around marketing profits in a low-volatility post-war world are "exaggerated".

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.